( BROOMFIELD Colo. April 24 2007 /PRN...)Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting,Health

BROOMFIELD, Colo., April 24, 2007 /PRNewswire/ -- Accera Inc. announced today that topline data from its Phase IIb study of its lead compound AC-1202 in Alzheimer's disease (AD) will be presented at the annual meeting of the American Academy of Neurology (AAN) in Boston. Judged by the AAN to be in the top five percent of the program, the data will also be featured in the Scientific Highlights Plenary Session.

Accera's vice president of clinical development Dr. Lauren Costantini will present the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session on Tuesday, May 1 at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The randomized, double-blinded, placebo-controlled Phase II trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD. Subjects visited the clinic on five occasions during the study to have their memory and other symptoms evaluated. Treatment lasted for three months and following a two-week washout, all subjects who had completed the three-month study were given the opportunity to participate in an open-label extension study. The open-label data will be presented at the Alzheimer's Association's International Prevention Conference in Washington, DC in early June.

About AC-1202

AC-1202 is an orally available, liquid compound that has been shown in preclinical studies to prevent the massive brain cell death seen in AD and other neurodegenerative diseases. Brain imaging techniques performed on AD patients reveal a decreased uptake of glucose, the brain's preferred source of energy. Efficiently converted by the liver into ketones, AC-1202 preserves the glucose-deprived brain cells with an alternative energy source. The potentially neuroprotective mechanism of AC-1202 is also being evaluated in age-associated memory impairment, Parkinson's disease, F
'"/>